Effect of Fibrinogen Substitution in Afibrinogenemia on Hemorheology and Platelet Function

Abstract

SummaryFibrinogen substitution can correct bleeding in afibrinogenemia. We assessed the effect of fibrinogen substitution in a patient lacking immunoreactive fibrinogen. Fibrinogen and thrombin time were not measurable before, but became detectable within 30 min after substitution, parallelled by an increase in ADP-induced platelet aggregation from <10% to 32%. Platelet adhesion, measured by Stagnation Point Flow Adhesio- Aggregometry, was notdetectable prior to substitution but attained normal values thereafter. Scanning electron microscopy of adhering platelets revealed pseudopodia protrusion and spreading. Morphometry revealed two populations of spread platelets one of which demonstrated inhibited spreading as compared to healthy controls. Immunoelectron microscopy revealed normal GPIIb/IIIa receptor expression, both before and after substitution. Dynamic and kinematic viscosity of plasma and whole blood remained below the 99.9% confidence border of a healthy control group. In afibrinogenemia fibrinogen levels as low as 10% of normal concentration sufficed to normalize coagulation, platelet adhesion, and, partially, spreading.

THIS ARTICLE HAS BEEN RETRACTED: Whole‐blood aggregometry: are there any limits with regard to platelet counts?

“…Therefore, WBA mainly depends on the platelet function in contrast to other approaches, e.g. thrombelastography comprising the global coagulation cascade 1,20 . Based on the fact not be adjustable to platelet count, concomitant factors cannot be standardized as well 4,14,20 …”

A deep intronic mutation inFGBcreates a consensus exonic splicing enhancer motif that results in afibrinogenemia caused by aberrant mRNA splicing, which can be corrected in vitro with antisense oligonucleotide treatment

“…We have demonstrated normalization of splicing in vitro using antisense morpholino oligonucleotides. Even if this is less efficient in vivo, it may still be adequate for therapeutic use, as fibrinogen levels as low as 10% of normal have been shown to normalize coagulation and platelet adhesion [Reininger et al, 1995]. However, before human treatment trials could begin there are several issues that need to be resolved.…”

Mutations in the fibrinogen gene cluster accounting for congenital afibrinogenemia: an update and report of 10 novel mutations

“…Another difficulty is to decide the level of fibrinogen that should be achieved when prophylaxis has been approved. Fibrinogen levels as low as 10% of normal was sufficient to normalize coagulation and platelet adhesion and partially normalize platelet spreading [Reininger et al, 1995]. It is also important to adjust a prophylactic schedule to each patient since the pharmacokinetics of fibrinogen after replacement therapy is highly variable among patients [Kreuz et al, 2005].…”